INTRODUCTION
============

Mortality rate of schizophrenia patients was found to be high, and cardiovascular diseases (CVD) have been shown to play an important role in this early mortality rate increase \[[@b1-pi-2019-0063]\]. Therefore, schizophrenia is considered to be a disease that shortens life \[[@b2-pi-2019-0063]\]. Obesity \[[@b3-pi-2019-0063],[@b4-pi-2019-0063]\], smoking \[[@b5-pi-2019-0063]\], changes in lipid and glucose levels \[[@b6-pi-2019-0063],[@b7-pi-2019-0063]\] and glucose intolerance due to medication are common in schizophrenia patients \[[@b8-pi-2019-0063]\]. Due to non-compliance with the treatment, there are also problems in the treatment of existing disturbances \[[@b9-pi-2019-0063]-[@b11-pi-2019-0063]\].

The Framingham risk score (FRS) is a gender-specific multivariate risk factor algorithm that can be used in the clinical setting to estimate the 10-year risk of CVD and individual cardiovascular events (coronary, cerebrovascular and peripheral artery disease, and heart failure) \[[@b12-pi-2019-0063]\]. The Framingham heart study helped to reduce cardiovascular mortality in developed countries by early detection of cardiovascular risk factors and measurement of this risk using FRS \[[@b13-pi-2019-0063]\]. FRS has been confirmed in several different populations \[[@b14-pi-2019-0063]-[@b18-pi-2019-0063]\] and more recently in mental patients \[[@b19-pi-2019-0063]\]. Studies in various countries have shown that the ten-year risk of CVD is significantly higher in schizophrenia patients than in healthy controls \[[@b20-pi-2019-0063]-[@b23-pi-2019-0063]\].

Some studies investigating the risk of CVD have focused on specific subgroups of schizophrenia patients, such as those over 40 years of age \[[@b24-pi-2019-0063]\], obese \[[@b25-pi-2019-0063]\], or those using various antipsychotics \[[@b26-pi-2019-0063]-[@b30-pi-2019-0063]\]. The current literature has linked the relationship between CVD and schizophrenia to many reasons such as antipsychotic drugs, age and genetic predisposition, unhealthy nutrition, sedentary lifestyles, and smoking \[[@b31-pi-2019-0063],[@b32-pi-2019-0063]\]. The only study which compared the degree of cardiovascular risk and the prevalence of metabolic syndrome in deficit and non-deficit schizophrenia patients, reported that patients with deficit schizophrenia were more obese and had a higher coronary heart disease risk than patients with non-deficit schizophrenia \[[@b33-pi-2019-0063]\]. From this point of view, it should also be considered whether there is a relationship between positive and negative symptoms and possible CVD risk in schizophrenia.

In this study, we aimed to investigate the relationship between the risk of heart disease and schizophrenia symptomatology by determining the estimated coronary heart disease risk percentages of schizophrenia patients. We hypothesised that patients with higher negative symptoms would face higher CVD risk.

METHODS
=======

The study was conducted in Psychosis outpatient unit and Community Mental Health Centerof Izmir Katip Çelebi University Atatürk Training and Research Hospital. A total of 109 patients with schizophrenia were included in the study. All the patients were informed about the study, and written informed consent was obtained. A sociodemographic information form was applied to 39 healty controls who did not have a psychiatric disease and who voluntarily agreed to participate in the study and gave written informed consent as a control group.

Sociodemographic information form, clinical evaluation scales and FRS were applied to all the subjects included in the study. Sociodemographic characteristics, age at onset, duration of illness, number of hospitalizations, the course of the disease and antipsychotic medications were recorded by sociodemographic information form. After the records were completed, The Scale for the Assessment of Negative Symptoms (SANS) \[[@b34-pi-2019-0063]\], The Scale for the Assessment of Positive Symptoms (SAPS) \[[@b34-pi-2019-0063]\], and Calgary Depression Scale for Schizophrenia (CDSS) \[[@b35-pi-2019-0063]\] were given to all participants.

The 10-year probability of developing general cardiovascular disease in both groups was calculated using a gender-specific multivariate risk factor algorithm found on the Framingham Heart Study website at <https://www.mdcalc.com/framinghamrisk-score-hard-coronary-heart-disease> \[[@b12-pi-2019-0063]\].

Since the study was considered as a follow-up study, the same clinical evaluation scales and the Framingham Risk Score calculation were planned to be repeated one year and ten years later. Preliminary cross-sectional results will be reported here. Approval for the analysis was obtained from the Izmir Katip Celebi University, Non-Interventional Clinical Studies Institutional Review Board with number 2018/317.

The Scale for the Assessment of Positive Symptoms (SAPS)
--------------------------------------------------------

It has been developed by Andreasen \[[@b34-pi-2019-0063]\] to measure the level, distribution and severity of positive symptoms in schizophrenia patients. There are four subscales and 34 items. It has been validated for Turkish language \[[@b36-pi-2019-0063]\].

The Scale for the Assessment of Negative Symptoms (SANS)
--------------------------------------------------------

Schizophrenia patients were developed by Andreasen \[[@b34-pi-2019-0063]\] to measure the level, distribution and severity of negative symptoms. A total of 5 subscales contain 25 items. It has been validated for Turkish language \[[@b37-pi-2019-0063]\].

Calgary Depression Scale for Schizophrenia (CDSS)
-------------------------------------------------

The CDS is a rating scale with a structured interview designed to assess depression in people with schizophrenia \[[@b35-pi-2019-0063]\]. Based on responses to questions asked by the interviewer, the patient is assigned a score ranging from zero to three on each item. These are depressed mood, sense of hopelessness, self-depreciation, guilty ideas of reference, pathological guilt, heightened depression in the morning in the morning, early wakening, suicide and an interviewer assessment of depression based on the entire interview. The Turkish validity and reliability study was conducted by Aydemir et al. \[[@b38-pi-2019-0063]\].

Framingham risk score
---------------------

It uses the information obtained from both the patient and current case records. 10-year general CVD risk; is calculated according to the gender-specific Cox regression model developed for the 2008 FRS, including the following variables: age, smoking, systolic blood pressure (SBP), total cholesterol and high-density lipoprotein cholesterol (HDL) levels and history of receiving medical treatment for hypertension.

RESULTS
=======

The mean age of the patients with schizophrenia was 45.1±10.3 years, and that of the control group was 45.6±10.0 years. No statistically significant difference was found between the groups in terms of age, gender, HDL and total cholesterol levels, SBP and having hypertension medication ([Table 1](#t1-pi-2019-0063){ref-type="table"}). However, in comparison to the control group, the patients' group had lower rate of the married participants (28.2% and 84.6%, respectively, p\<0.01), and higher rate of smoking (56.3% and 23.0%, respectively, p\<0.01) ([Table 1](#t1-pi-2019-0063){ref-type="table"}). The mean score of FRS in patients with schizophrenia was 5.16±6.5, and that of the control group was 3.02±4.2 (p=0.030). Ten patients were receiving anti-hypertensive medications.

No significant correlation was found between FRS scores and SANS, SAPS, and CDSS scores. However significant correlation was found between FRS scores, and age, number of hospitalization and duration of disease (r=0.300, 0.261, 0.252, respectively).

When logistic regression analysis was performed to determine the factors associated with the FRS score in patientswith schizophrenia, age at onset of schizophrenia, the course of the disease, number of hospitalization, duration of disease, SANS, SAPS and CDSS were entered as independent variables; only number of hospitalization and duration of disease were found as significant predictors of FRS ([Table 2](#t2-pi-2019-0063){ref-type="table"}).

The medication breakdown were as follows: 88 (85.4%) on atypical antipsychotics, 7 (6.7%) on typical antipsychotics and 8 (7.7%) on both. Sixty-four (62.1%) of the patients were using antipsychotics and 35 (34.0%) were using antipsychotic and antidepressant, 3 (2.9%) were using antipsychotic and mood stabilizer, and 1 (1.0%) were using all the three. No statistical significant differences were found between the groups with regard to SANS; SAPS, CDSS, and FRS scores.

When patients on antipsychotic therapy were compared with regard to number of antipsychotics they were using; the patients who were using one antipsychotic therapy had higher HDL levels, and lower FRS scores, higher SAPS scores and higher number of hospitalizations compared to patients using 2 or more antipsychotic drugs (p=0.048, 0.008, 0.020, 0.002, respectively). There were no statistically significant differences with regard to the number of antipsycotics used and age, age at schizophrenia onset, duration of disease, tolal cholesterol, SBP, SANS, CDSS ([Table 3](#t3-pi-2019-0063){ref-type="table"}).

We also investigated whether the way of administration of antipsychotics were administered has an effect on FRS. Of the patients in our study, 65 were using only oral antipsychotics, 12 were using only long acting injectable antipsychotics (LAİA), 26 were using both of them, and FRS scores of the groups were as follows respectively; 46.83; 53.79; 64.10. Kolmogorov-Smirnov test showed that the distrubition wasn't normal across categories. Therefore, Kruskal-Wallis test was performed on FRS. There was a significant difference between the three groups (p=0.044). When the Mann-Whitney U test was applied to determine which groups the difference originated from, it was found that the difference between patients using oral antipsychotics and patients using both LAİA and oral antipsychotics was significant (p=0.011).

DISCUSSION
==========

The results of our study showed that the prevalence of FRS (5.16%) in schizophrenia patients was significantly higher than the general reference population (3.02%). This result is consistent with other studies investigating the 10-year risk of cardiovascular disease with FRS in patients with schizophrenia \[[@b20-pi-2019-0063]-[@b22-pi-2019-0063],[@b39-pi-2019-0063],[@b40-pi-2019-0063]\], and is close to 5.9%, which is the result of the single study in this topic in our country \[[@b23-pi-2019-0063]\].

To the best of our knowledge, this is the first study to explore the relationship between positive and negative symptoms and possible CVD risk in schizophrenia. In our study, no significant relationship was found between FRS and schizophrenia symptoms. However, 10-year CVD risk was associated with the duration of the disease and the number of hospitalizations. These results show that the 10-year risk of CVD is related to the severity of the disease and the duration of the disease in general, rather than the cross-sectional severity of the disease.

Both genetic and environmental factors are considered in the etiology of CVD that can shorten the life expectancy of patients with schizophrenia. The first studies in the field of genetics and epigenetics are related to the risk factors of CVD such as metabolic syndrome and diabetes mellitus \[[@b41-pi-2019-0063]\]. Presence of high blood sugar levels in patients with severe mental illness before antipsychotic period \[[@b42-pi-2019-0063]\], and impaired glucose tolerance test in first-episode antipsychotic naïve patients \[[@b43-pi-2019-0063]\] and their healthy relatives \[[@b44-pi-2019-0063]\] suggest that genetics have an effect on the etiology of cardiovascular risk factors in these patients. In this point of view some studies investigated whether some common candidate genes are present in both schizophrenia and cardiovascular risk factors. Genetic assosiacions were found between atypical antipsychotic-related weight gain and INSIG2 \[[@b45-pi-2019-0063]\], rs498177 single nucleotide polymorphism (SNP) in the serotonin 5-HT2C receptor gene and metabolic syndrome only in female patients with schizophrenia \[[@b46-pi-2019-0063]\] and endothelial nitric oxide synthetase (eNOS) T-786C genetic variant and endothelial functioning \[[@b47-pi-2019-0063]\].

In studies on mRNA in schizophrenia, different alterations among mRNA were reported in rats treated with haloperidol \[[@b48-pi-2019-0063]\], in the postmortem brains of schizophrenia patients \[[@b49-pi-2019-0063]\] and also inperipheral blood mononuclear cells in vivo in schizophrenia patients \[[@b50-pi-2019-0063]\]. In a study investigating the effect of the treatment with antipsychotics on changes in miRNA expression, neurologically and metabolically relevant miRNA-gene interaction networks were identified in patients treated with olanzapine \[[@b51-pi-2019-0063]\].

There is much more research into the environmental factors in the etiology of CVD in schizophrenia. Tobacco smoking seems to be an important environmental factor for increasing CVD rates given its expected high prevalence within this type of patients \[[@b52-pi-2019-0063],[@b53-pi-2019-0063]\]. As in the general population, smoking contributes to the reduced life expectancy in patients with schizophrenia \[[@b22-pi-2019-0063]\]. Our results have shown also an elevated prevalence of smoking tobacco in patients with schizophrenia than in the Turkish general population. These results are consistent with worldwide literature \[[@b53-pi-2019-0063]-[@b57-pi-2019-0063]\]. With smoking, unhealthy behaviors, high-fat, low-fibre diets and lack of exercise; appears to be the other possible environmental causes of CVD, which is observed to be very high among patients with schizophrenia and other serious mental illnesses \[[@b20-pi-2019-0063],[@b58-pi-2019-0063],[@b59-pi-2019-0063]\]. Consequently, the duration of exposure to these causes also prolongs as the duration of the disease is prolonged. In our study, the relationship between FRS and disease duration may be associated with increased exposure to these factors.

On the other hand, in our study, the use of more than one antipsychotic was also associated with FRS. Previous studies have consistently reported that antipsychotic medication is associated with increased risk for a range of cardiometabolic disorders \[[@b60-pi-2019-0063],[@b61-pi-2019-0063]\], and use of antipsychotic polypharmacy and higher antipsychotic dosages are linked to increased cardiovascular-related mortality \[[@b62-pi-2019-0063]\], and negative effects on life expectancy \[[@b63-pi-2019-0063],[@b64-pi-2019-0063]\] in people with schizophrenia and schizophrenia spectrum disorders. Beside this antipsychotic polypharmacy is widely prevalent, is prescribed for long durations, and is an increasing phenomenon among schizophrenia patients, indicating a significant discrepancy with treatment guidelines \[[@b65-pi-2019-0063]\]. A meta-analysis based on 10 observational studies, suggested that antipsychotic use might be a potential risk factor of myocardial infarction \[[@b66-pi-2019-0063]\].

In addition, according to the results of our study, we found that the route of administration of antipsychotics also had an effect on FRS, and patients using both oral and LAİA were found to have a higher risk of heart disease than those using oral therapy alone. However, this difference may be due to polypharmacy rather than the administration of the drug. Previous studies have shown a high prevalence of metabolic syndrome and cardiovascular risk in psychotic patients treated with long-acting injectable antipsychotics \[[@b67-pi-2019-0063],[@b68-pi-2019-0063]\]. Compared to oral antipsychotic treatment, LAİA has been shown to have more efficacy, less extrapyramidal symptoms and greater weight gain \[[@b69-pi-2019-0063],[@b70-pi-2019-0063]\]; our study was the first comparative study in terms of cardiovascular effects.

Some limitations of the current study should be mentioned. First, this was a cross-sectional analysis. Another limitation concerns possible influences on the relationships between antipsychotics and cardiometabolic health (such as levels of medication adherence, antipsychotic daily defined dose equivalent, duration of exposure to antipsychotic regimens, family risk factors and lifestyle behaviours) are potential unmeasured confounding variables. In addition, the relatively small sample size may have increased the risk of errors and may have prevented the statistical investigation of the effect of each antipsychotic on CVD.

Our results are consistent with the concept that CVD risk is higher in patients with schizophrenia than the general population \[[@b1-pi-2019-0063],[@b19-pi-2019-0063],[@b21-pi-2019-0063]-[@b24-pi-2019-0063]\]. Additionally, our findings show the relationship between CVD and the duration and overall severity of the disease but not the cross- sectional psychopathology, and also highlights the undeniable role of antipsychotics in this relationship. Monitoring of patients on antipsychotic therapy should not only focus on the psychotic symptoms, but should also consider possible cardiac and metabolic disorders associated with the treatment. Physicians should identify specific measures to counteract these negative events, focusing on changes in lifestyle, diet, exercise, and the use of specific drugs to treat metabolic disorders. These measures, if appropriate, may include assessing the change of antipsychotic treatment by the psychiatrist and avoiding polypharmacy as much as possible. Improving our understanding of cardiovascular risk in patients with schizophrenia may help to develop preventive and therapeutic programs in this vulnerable population.
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###### 

Demographic and clinical characteristics of the groups

                              Schizophrenia   Healthy control   X        p
  --------------------------- --------------- ----------------- -------- -------------------------------------------------------
  Gender                                                                 
   Female                     51 (49.5)       21 (53.8)         0.212    0.645
   Male                       52 (50.5)       18 (46.2)                  
  Marital status                                                         
   Married                    29 (28.1)       33 (84.6)         37.020   \<0.000^[†](#tfn2-pi-2019-0063){ref-type="table-fn"}^
   Single                     74 (71.9)       6 (15.3)                   
  Smoking                                                                
   Absent                     45 (43.6)       30 (76.9)         12.538   \<0.000^[†](#tfn2-pi-2019-0063){ref-type="table-fn"}^
   Present                    58 (56.4)       9 (23.1)                   
  Hypertension medication                                                
   Absent                     93 (90.2)       37 (94.8)         1.177    0.555
   Present                    10 (9.8)        2 (5.2)                    
  Age                         45.1±10.3       45.6±10.0                  0.789
  HDL cholesterol (mg/dl)     44.7±14.3       48.18±13.6                 0.192
  Total cholesterol (mg/dl)   200.5±46.9      190.6±52.9                 0.314
  SBP                         118.6±14.5      115.1±21.5                 0.357
  FRS                         5.16±6.5        3.02±4.2                   0.030^[\*](#tfn1-pi-2019-0063){ref-type="table-fn"}^

p\<0.05,

p\<0.001.

HDL: high-density lipoprotein cholesterol, SBP: systolic blood pressure, FRS: Framingham Risk Score

###### 

Logistic regression analyses onto FRS scores in patients with schizophrenia

  Model   R                                                      Change statistics                     
  ------- ------------------------------------------------------ ------------------- ------- --- ----- -------
  1       0.261^[\*](#tfn3-pi-2019-0063){ref-type="table-fn"}^   0.068               7.334   1   100   0.008
  2       0.335^[†](#tfn4-pi-2019-0063){ref-type="table-fn"}^    0.044               4.870   1   99    0.030

predictors: (constant), number of hospitalization,

predictors: (constant), number of hospitalization, duration of disease.

FRS: Framingham Risk Score

###### 

Comparison of patients using single or multiple antipsychotic drugs with regard to SANS, SAPS, CDSS, FRS and disease-related variables

  Number of antipsychotics    ≥2 (N=46)     \<2 (N=57)    p
  --------------------------- ------------- ------------- ------------------------------------------------------
  Age                         44.67±9.3     45.44±11.2    0.712
  Age of onset                27.00±9.0     28.30±11.1    0.526
  Number of hospitalization   4.37±4.6      2.05±2.7      0.002^[†](#tfn6-pi-2019-0063){ref-type="table-fn"}^
  Duration of disease         17.09±9.6     16.32±10.8    0.707
  HDL cholesterol             41.67±13.7    47.28±14.3    0.048^[\*](#tfn5-pi-2019-0063){ref-type="table-fn"}^
  Total cholesterol           202.52±41.4   198.89±51.3   0.699
  SBP                         120.30±15.9   117.25±13.3   0.292
  FRS score                   7.09±7.4      3.69±5.1      0.008^[†](#tfn6-pi-2019-0063){ref-type="table-fn"}^
  SANS                        26.39±22.3    26.88±20.0    0.908
  SAPS                        14.67±17.5    7.33±14.1     0.020^[\*](#tfn5-pi-2019-0063){ref-type="table-fn"}^
  CDSS                        3.13±4.2      2.89±4.6      0.790

p\<0.05,

p\<0.001.

HDL: high-density lipoprotein cholesterol, SBP: systolic blood pressure, FRS: Framingham Rsik Score, SANS: Scale for the Assessment of Negative Symptoms, SAPS: Scale for the Assessment of Positive Symptoms, CDSS: Calgary Depression Scale for Schizophrenia
